^
    Tempus xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII.
    Cancer:
    Solid Tumor
    Gene:
    EGFR (Epidermal growth factor receptor), MET (MET proto-oncogene, receptor tyrosine kinase)
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    06/21/23
    ST
    -
    FDA (PMA)